Geftinat 250 mg Tab

Gefitinib belongs to a class of medications known as tyrosine kinase inhibitors, specifically targeting the epidermal growth factor receptor (EGFR), a protein that can drive uncontrolled cell growth when mutated. By blocking this receptor's activity, Gefitinib helps slow or stop the growth and spread of cancer cells that rely on this particular pathway. It is commonly used to treat non-small cell lung cancer in patients whose tumors have specific EGFR gene mutations, which are identified through genetic testing to help determine if this targeted approach is likely to be effective. This precision approach allows treatment to be tailored to the specific characteristics of an individual's cancer, often providing meaningful benefit for patients with these particular mutations. As an oral targeted therapy, Gefitinib offers a more convenient treatment option compared to intravenous chemotherapy, allowing much of the treatment to take place at home between clinical check-ins. The tablets are typically taken once daily, following a schedule established by an oncologist based on the patient's specific cancer characteristics and response to treatment. Regular monitoring, including imaging studies and periodic check-ins, helps track treatment response and guide any necessary adjustments. Many patients with EGFR-mutated lung cancer experience meaningful tumor response and improved disease management with Gefitinib as part of their treatment plan. As with all targeted cancer therapies, Gefitinib tablets should be used strictly under the guidance of an experienced oncology healthcare provider.